Insulet Corporation, a leading medical device company, has recently announced a forecast of weak annual revenue growth. This news has led to a drop in the company's shares, causing concern among investors and analysts.
Insulet, known for its innovative insulin delivery systems, revealed that it expects its revenue growth to be lower than previously anticipated. The company cited various factors contributing to this forecast, including increased competition in the market and supply chain challenges.
